I. Platelet-Rich Plasma

Your blood already contains the tools your body needs to heal. Platelet-Rich Plasma — known as PRP — is a therapy that concentrates those tools and delivers them precisely where healing is needed most.

PRP is prepared from a small sample of your own blood, which is processed to concentrate the platelets and the growth factors they carry. When injected into a damaged joint, tendon, ligament, or spinal structure under image guidance, PRP signals your body to initiate a targeted healing response — reducing inflammation, stimulating tissue repair, and supporting long-term recovery.

Dr. Mahajer uses PRP as a steroid-sparing alternative across a broad range of orthopedic and musculoskeletal conditions. Corticosteroid injections have a well-established role in pain management, but repeated use can accelerate tissue breakdown over time. PRP offers a biologically active option that works with your body’s own healing mechanisms rather than simply suppressing symptoms.

“Platelet-rich plasma significantly reduced pain and improved function compared to corticosteroid injection in patients with knee osteoarthritis, with effects sustained at 12-month follow-up.” — Kon E, et al. Knee Surg Sports Traumatol Arthrosc. 2011;19(4):528–535.

Dr. Mahajer applies PRP only within evidence-based indications — conditions where the published literature supports its use and where the clinical picture justifies it. These include knee osteoarthritis, rotator cuff tendinopathy, lateral epicondylosis, patellar tendinopathy, gluteal tendinopathy, plantar fasciitis, and selected spinal applications. He does not apply PRP indiscriminately or promise outcomes the current evidence does not support.

Every PRP treatment begins with a thorough evaluation to confirm that PRP is the right tool for your specific condition, your specific tissue, and your specific goals. The preparation protocol, injection technique, and post-procedure rehabilitation plan are all tailored individually — because the same intervention applied carelessly produces very different results than the same intervention applied with precision.

If you have been managing a joint, tendon, or spinal condition with repeated steroid injections — or if you have been told that surgery is your next step — PRP may offer a meaningful alternative. Dr. Mahajer will review your history and imaging, assess whether PRP is appropriate for your condition, and explain what the evidence realistically supports before any recommendation is made.

II. Cell-Rich Concentrate

For more advanced conditions — where the degenerative process is further along, where PRP alone may not be sufficient, or where the tissue requires a stronger biological signal — Dr. Mahajer offers Cell-Rich Concentrate derived from Bone Marrow Aspirate Concentrate, or BMAC.

BMAC is harvested from your own bone marrow — typically from the posterior iliac crest — using a minimally invasive aspiration technique performed in the office or procedural setting. The harvested marrow is then processed to concentrate the cells and growth factors it contains. Like PRP, it is entirely derived from your own body. No foreign substances. No donor material. Your own biology, concentrated and precisely delivered.

The cells within BMAC are believed to carry a more potent and more complex signaling system than platelets alone. They communicate with the surrounding tissue in ways that may promote a stronger regenerative response — making BMAC a consideration for conditions such as advanced joint arthritis, more significant tendon pathology, avascular necrosis, and selected spinal applications where the structural damage is more substantial.

“Bone marrow aspirate concentrate demonstrated superior outcomes compared to PRP alone in patients with moderate-to-severe knee osteoarthritis, suggesting a more robust regenerative signaling profile.” — Centeno C, et al. Stem Cells Transl Med. 2018;7(1):55–63.

Dr. Mahajer is transparent about what the science does and does not yet confirm. The regenerative medicine field is evolving rapidly, and he stays current with the published literature, attends specialty meetings, and incorporates new evidence as it emerges. He will communicate the actual science to you honestly — what is well-supported, what is promising but not yet definitive, and what remains under investigation.

Not all regenerative products are created equal — and some are not evidence-based at all. Dr. Mahajer does not recommend clinics selling over-the-counter or commercially sourced “stem cell” products. Many of these products contain few if any viable cells, are not derived from your own body, and are not supported by peer-reviewed clinical evidence. The marketing in this space is aggressive and often misleading.

If you have seen advertisements for “stem cell therapy” at a discounted price, or been approached by a clinic promising dramatic results from a commercially sold product, exercise significant caution. When in doubt, ask for the published clinical evidence. A physician who cannot provide it should not be administering the treatment. Dr. Mahajer will always show you the evidence behind every recommendation he makes.

III. Regenerative Research

Regenerative medicine is one of the most active and rapidly evolving frontiers in spine and musculoskeletal care. The treatments available today — and the indications that guide their use — are the product of years of clinical investigation. The treatments available in the years ahead will be shaped by the research being conducted right now.

Dr. Mahajer is not only a practitioner of regenerative medicine — he is an active contributor to its scientific foundation. As Principal Investigator on prospective multicenter clinical trials, he participates in the rigorous process of evaluating novel regenerative therapies: designing protocols, enrolling and following patients, collecting and analyzing outcome data, and contributing to the published literature that guides the field.

“Participation in well-designed clinical trials remains the highest standard by which the safety and efficacy of emerging regenerative therapies can be established and communicated to the medical community.” — Shapiro SA, et al. Am J Sports Med. 2019;47(12):3004–3011.

This research engagement is not separate from his clinical practice — it is inseparable from it. A physician who is actively involved in clinical investigation understands the current state of the evidence with a depth that cannot be acquired from reading journals alone. He understands the gaps, the limitations, the promising signals, and the questions that remain unanswered. That understanding informs every clinical recommendation he makes.

It also means that eligible patients may have access to investigational therapies through monitored clinical trial participation — treatments that are not yet commercially available but are being rigorously evaluated under FDA oversight. Dr. Mahajer will discuss trial eligibility with appropriate patients and explain what participation involves in full.

When Dr. Mahajer recommends a regenerative treatment, that recommendation is grounded in both clinical experience and active research engagement. He will tell you what the evidence supports, what it does not yet support, and where the field is heading. You will never be asked to accept a treatment on faith alone — you will be given the science, in plain language, so you can make an informed decision.

PAIN SHOULD NOT DEFINE WHAT YOU ARE ABLE TO DO

Dr. Mahajer is ready to help you find a better path forward.